TRACEY RH PRICE

Allopathic & Osteopathic Physicians|Internal Medicine BRUNSWICK, GA NPI 1558779348

General Payments — all program years on this page

$2,329.61

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 116
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $354.36 across 18 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $354.3618

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
Novo Nordisk AS $95.315
Acerta Pharma LLC $93.784
Lilly USA, LLC $36.222
GlaxoSmithKline, LLC. $34.922
DEXCOM, INC. $20.071
Exact Sciences Corporation $19.631
Abbott Laboratories $18.651
Astellas Pharma US Inc $17.961
Medtronic, Inc. $17.821

By program year

Program yearAmountRecords
2018 $68.665
2019 $375.2323
2020 $486.7532
2021 $455.1916
2022 $444.0714
2023 $145.358
2024 $354.3618

Records — PY2024 (18)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1097062547 Novo Nordisk Inc $17.90 03/21/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1097383572 Novo Nordisk Inc $17.65 01/22/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1097405336 Novo Nordisk Inc $16.19 07/30/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1097715765 Novo Nordisk Inc $22.35 06/18/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1097753383 Novo Nordisk Inc $21.22 12/20/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105486689 AstraZeneca Pharmaceuticals LP $24.17 07/17/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105533756 AstraZeneca Pharmaceuticals LP $20.52 03/26/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105605599 AstraZeneca Pharmaceuticals LP $31.75 08/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105622121 AstraZeneca Pharmaceuticals LP $17.34 09/24/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1114551169 Exact Sciences Corporation $19.63 07/18/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116376032 GlaxoSmithKline, LLC. $14.31 04/30/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116570077 GlaxoSmithKline, LLC. $20.61 09/16/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1119376518 Medtronic, Inc. $17.82 01/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1125126077 Abbott Laboratories $18.65 02/04/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135460510 Lilly USA, LLC $19.11 09/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135483775 Lilly USA, LLC $17.11 04/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1139315776 Astellas Pharma US Inc $17.96 02/26/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1153341651 Dexcom, Inc. $20.07 04/23/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.